Diagnostics

Veracyte's Decipher test isn't just guiding prostate cancer treatment; its whole-transcriptome engine is building an unassailable commercial diagnostics moat.

As federal research stalls, a coalition of tech and finance veterans is injecting $15 million into a nimble clinical network targeting the biological roots of Long COVID and chronic Lyme disease.

Slingshot Biosciences elevates its COO to CEO, signaling a strategic shift toward aggressive biomanufacturing scale-up and resolving cell therapy bottlenecks.

Profusa's injectable biosensor cleared a major EU regulatory hurdle, but severe cash constraints and a massive pivot raise existential questions for the company.

Mira's new Cortisol Pattern Kit challenges wearable tech by measuring actual biological stress markers in urine, but is more data always better for our health?

Ontario's publicly funded fetal DNA screening replaces universal injections with precision medicine, optimizing healthcare resources and securing Canada's blood supply.

A high-profile Washington gala reveals the strategic maneuvering of biotechnology startups navigating the multibillion-dollar early cancer detection market.

ABL Texcell Diagnostics’ phased acquisition of Vela’s US and Asian assets highlights a masterclass in post-pandemic medtech consolidation.

Novo Nordisk and Siemens Healthineers are rewriting the commercialization playbook by pairing blockbuster metabolic drugs with accessible blood diagnostics.

Koning Health’s recent TGA approval for its compression-free breast CT system signals a strategic shift in diagnostic imaging and patient compliance.

The Euronext-listed firm is moving beyond equipment sales, creating a recurring revenue engine in Brazil's $9B oncology diagnostics market via a novel partnership.

A landmark partnership is digitizing millions of tissue samples across Europe, centralizing expertise and paving the way for AI-driven precision medicine.

The oncology firm's revenue dips and losses widen, but a strategic shift to hospitals and key regulatory wins may pave the way for long-term growth.

Miami's DermaSensor lands $5M and four major US partnerships, setting the stage to rapidly scale its FDA-cleared AI skin cancer detection device nationwide.

Bracco Imaging enters the cell therapy toolkit market with BubbleGen, a microbubble tech aiming to replace magnetic beads for T-cell isolation. Can it solve CAR-T's biggest bottlenecks?

Nearly 37 million Americans face an invisible crisis of dizziness and imbalance, fueling a public health emergency. But new awareness and therapies offer a path to stability.

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?

Newly restructured Niki BioSolutions faces Wall Street at a key conference, pitching its brain health innovations while battling steep losses and investor doubt.

Pearl’s new FDA-cleared 3D imaging AI is set to democratize advanced diagnostics, empowering general dentists to see more and reshaping patient care.

Kala Bio's new deal with Virotek isn't just about eye care. It's a capital-efficient pivot that tests its new identity and bets on a commercial present.